Baicalin, a flavonoid compound extracted from the roots of Scutellaria baicalensis (Chinese skullcap), has been studied for its potential effects in the management of asthma. While Baicalin has a long history of use in Traditional Chinese Medicine for various inflammatory conditions, including respiratory ailments, scientific research over the past two decades has specifically explored its mechanisms relevant to asthma.

Preclinical studies, primarily in animal models and cell cultures, indicate that Baicalin exhibits anti-inflammatory, antioxidant, and immunomodulatory effects. It has been shown to inhibit the production of pro-inflammatory cytokines (such as IL-4, IL-5, and IL-13), reduce eosinophil infiltration in the airways, suppress airway hyperresponsiveness, and decrease mucus secretion. These effects are mediated through pathways involving NF-κB and MAPK signaling, which are implicated in asthma pathophysiology.

However, direct clinical evidence in humans is limited. Most studies to date are preclinical, with only a few small-scale clinical trials or case reports suggesting possible benefits. Thus, while scientific rationale exists and animal studies are promising, the lack of robust human trials limits the strength of the evidence to support Baicalin as a treatment or adjunct for asthma.

In summary, Baicalin’s use for asthma is supported by scientific investigation at the preclinical level, but its efficacy and safety in humans remain to be established through larger, well-designed clinical trials.